Portfolio news 0

Newcastle, UK, 14 October 2025: Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs), will present new data from its Phase 1 study of IKS014, a human epidermal growth factor receptor 2 (HER2) ADC, in patients with advanced HER2+ solid tumours, at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany (17-21 October).

Poster Presentation details:

Abstract Title: A Phase 1 Dose Escalation Trial of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants with Advanced HER2+ Solid Tumors

Session Title: Developmental Therapeutics

Date/Time: 19 October 2025/12:00-12:45 CET

Location: Level 2, Hall 25

Poster Number: 936P

The Phase 1 study (NCT05872295) is a non-randomised, open-label, multicentre trial evaluating IKS014 in patients with locally advanced or metastatic solid tumours that express HER2. Data will be presented from the dose escalation portion of the trial conducted in Australia, which was designed to establish the Maximum-tolerated dose and/or Recommended Phase 2 Dose for IKS014 as monotherapy and to provide initial safety, tolerability, efficacy, PK, PD, and immunogenicity characteristics of the ADC.